| Date |
Subject |
Media |
| 2025-09-02 |
Healthy Ageing Tech Show Opens — President Lai: Three Major Policies to Create an Age-Friendly Environment and Unlock Business Opportunities
|
The second Healthy Ageing Tech Show held its opening ceremony on the 8th. In his remarks, President Lai Ching-te stated that, in response to the advent of a super-aged society, the government has introduced three major policies to create an age-friendly environment and open up new business opportunities, aiming to make Taiwan a model of happiness among aging nations worldwide. The market scale for the ageing sector is expected to reach NT$3.6 trillion by 2025. |
| 2025-09-01 |
From Smart Care to Active Ageing: Healthy Ageing Tech Show Highlights Urban Innovation
|
As Taiwan’s ageing population grows rapidly, cities and counties are rolling out innovative strategies to address the diverse needs of older adults in daily living, healthcare, and lifelong learning. At this year’s Healthy Ageing Tech Show, the Age-Friendly Cities Pavilion drew significant attention, showcasing interactive exhibits, smart technology applications, and local service achievements that reflect Taiwan’s efforts to build an elder-friendly society. From smart healthcare and long-term care innovation to active ageing learning and lifestyle experiences, the exhibition demonstrated how cities are taking forward-looking actions to support ageing well. |
| 2025-09-01 |
Andros Pharmaceuticals Partners with Yung Shin Pharmaceutical to Enter the Topical Dermatology Market
|
Andros Pharmaceuticals announced on the 7th that it has signed a co-development and licensing agreement with Yung Shin Pharmaceutical Industrial, establishing a long-term strategic partnership. Initially, the two companies will collaborate to develop a high-value, high-margin niche generic drug, with Taiwan as the first target market, and will subsequently explore opportunities to expand into international markets. |
| 2025-09-01 |
Lin BioScience’s Subsidiary Belite Secures Additional US$15 Million Investment from Major International Fund
|
Belite, a subsidiary of Lin BioScience, announced that it has received an additional US$15 million investment (approximately NT$450 million) from the same major international fund. The financing was executed through the issuance of one American Depositary Share (ADS) and one unit of warrants per package, at US$65 per ADS (approximately NT$1,933 per share). Each warrant allows the purchase of one ADS at the same exercise price of US$65. The proceeds will be used to strengthen working capital and for general corporate purposes. |
| 2025-09-01 |
Healthy Ageing Tech Show Opens a Journey of Renewed Youth
|
Taipei World Trade Center Hall 1 Hosts Six Themes and Six Signature Events, Creating a Future of Longevity Without Long-Term Care |
| 2025-09-01 |
VIZIONFOCUS to Launch Two New Production Lines in September, Monthly Output to Reach 57 Million Lenses
|
VIZIONFOCUS, a contact lens manufacturer, announced that its consolidated revenue for July 2025 was NT$280 million, representing a 6.38% decline from the previous month but an increase of 20.82% compared to the same period last year. The month-on-month decrease was primarily due to cooling demand after the “618 Shopping Festival.” For the first seven months of 2025, cumulative consolidated revenue reached NT$1.97 billion, a 13.50% year-on-year increase. |
| 2025-08-28 |
Cardio Ring’s Next-Generation Blood Pressure Monitoring System ArteVu Secures U.S. FDA Clearance, Ushering in a New Era of Medical Monitoring
|
Cardio Ring, a U.S.-based medtech company founded by a Taiwanese team in Silicon Valley, has successfully developed ArteVu, an innovative blood pressure monitoring device capable of continuous measurement without the need for a cuff. On July 30, 2025, ArteVu received U.S. FDA clearance, marking another milestone for Taiwan’s smart healthcare technology on the global stage. |
| 2025-08-28 |
CHC Healthcare Reports NT$49.09 Million in First-Half Profit, Nearly Quadrupling QoQ; Growth to Continue Each Quarter in H2
|
CHC Healthcare Group announced its first-half financial results on the 6th, posting a net profit after tax of NT$49.098 million, up 61.4% year-on-year, with earnings per share (EPS) of NT$0.28. Second-quarter net profit after tax reached NT$40.696 million, a 3.84-fold surge compared to NT$8.402 million in the first quarter. |
| 2025-08-28 |
Acer Medical’s AI Healthcare Software Adopted by Over 500 Medical Institutions Worldwide
|
Acer Medical, a subsidiary of Acer, announced yesterday (6th) that its artificial intelligence (AI) healthcare software solutions have been successfully implemented in more than 500 medical institutions worldwide, including clinics, major hospitals, and diagnostic centers. The deployments span across Taiwan, Japan, Southeast Asia, Central America, and Europe, marking a significant milestone that highlights Acer Medical’s expertise in advancing AI applications for clinical decision support and early disease screening, as well as the strong global demand for smart healthcare solutions. |
| 2025-08-28 |
PharmaEssentia’s July Revenue Surges Past NT$1.3 Billion, Setting New Record
|
PharmaEssentia’s rare blood cancer drug Ropeg continued to deliver strong sales performance in the U.S. and global markets, driving the company’s July revenue to NT$1.3 billion, a historic monthly high, representing an 8.76% increase from June and a 48.01% increase year-on-year. Cumulative revenue for January through July reached NT$8.16 billion, up 68.65% year-on-year. |
